866-997-4948(US-Canada Toll Free)

Colorectal Cancer Therapeutics Market in APAC 2015-2019

Published By :

Technavio

Published Date : Dec 2015

Category :

Cancer

No. of Pages : 106 Pages

About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
APAC
China
Japan

Key vendors
Amgen
Bayer
Bristol-Myers Squibb
Chugai Pharmaceuticals
Merck
Sanofi

Other prominent vendors
Accord Healthcare
Advenchen Laboratories
Aeterna Zentaris
AstraZeneca
AVEO Oncology
Bavarian Nordic
Biothera
Boehringer Ingelheim
Boston Biomedical
Cancer Prevention Pharmaceuticals
Celator Pharmaceuticals
Daiichi Sankyo
Debiopharm
Eisai
Eli Lilly
EpicentRx
GlaxoSmithKline
Hutchison Medipharma
Immodulon Therapeutics
Immunomedics
MacroGenics
Merrimack Pharmaceuticals
MolMed
Mologen
Morphotek
Mylan
Nektar Therapeutics
Oncothyreon
Otsuka Pharmaceutical
PledPharma
Precision Biologics
PsiOxus Therapeutics
Sun Pharmaceutical
Symphogen
Taiho
Takeda
Teva Pharmaceuticals
ThromboGenics
Xbiotech
Yakult Honsha

Key market driver
Increase in aging population
For a full, detailed list, view our report

Key market challenge
Unknown disease etiology
For a full, detailed list, view our report

Key market trend
Rise in public awareness
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
Vectibix
PART 03: Product profiles
Stivarga
Erbitux
Xeloda
Avastin
Zaltrap
PART 04: Market research methodology
Research methodology
Economic indicators
PART 05: Introduction
Key market highlights
PART 06: Disease overview
Understanding the disease
High risk factors
Signs and symptoms
Pathophysiology
Diagnosis
Staging
Biomarker testing
Epidemiology
Treatment
PART 07: Pipeline portfolio
Information on pipeline candidates
PART 08: Market landscape
Market overview
Market size and forecast
Colorectal cancer therapeutics market in Japan
Colorectal cancer therapeutics market in China
Five forces analysis
PART 09: Market segmentation by based on the type of molecules
Small molecules
Biologics
PART 10: Market segmentation by route of administration
Oral
Parenteral
PART 11: Market segmentation by lines of chemotherapy
First-line chemotherapy
Second-line chemotherapy
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
Amgen
PART 18: Key vendor analysis
Bayer HealthCare
Bristol-Myers Squibb
Chugai Pharmaceutical
Merck
Sanofi
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
Exhibit 01: Product offerings
Exhibit 02: High risk factors for colorectal cancer
Exhibit 03: Signs and symptoms of colorectal cancer
Exhibit 04: Diagnostic tests for colorectal cancer
Exhibit 05: Staging for colon cancer
Exhibit 06: Staging for rectal cancer
Exhibit 07: Types of genes
Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
Exhibit 11: Estimated incidence in adult population in APAC 2012
Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
Exhibit 14: Treatment options for colorectal cancer
Exhibit 15: Types of surgical procedure for colorectal cancer
Exhibit 16: Types of radiation therapy for colorectal cancer
Exhibit 17: Types of targeted therapy
Exhibit 18: Summary of approved cancer drugs for colon cancer
Exhibit 19: Pipeline molecules for colorectal cancer
Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
Exhibit 23: Five forces analysis
Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
Exhibit 27: Use of branded targeted therapies in China and Japan 2013
Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
Exhibit 29: Impact of drivers
Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
Exhibit 34: Amgen: Key takeaways
Exhibit 35: Bayer: Key takeaways
Exhibit 36: Bristol-Myers Squibb: Key takeaways
Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 39: Chugai Pharmaceutical: Key takeaways
Exhibit 40: Merck: Key takeaways
Exhibit 41: Sanofi: Key takeaways
Exhibit 42: Amgen: Business segmentation by revenue 2014
Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Amgen: Geographical segmentation by revenue 2014
Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Sanofi: Business segmentation by revenue 2014
Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 59: Sanofi: Geographical segmentation by revenue 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *